Kornimate/medical-research-clean huggingface dataset:
ability of carotid sonography and inferior vena cava sonography for the prediction of post-induction hypotension in hypertensive patients

Conditions: General Anesthesia

Summary: hypertensive patients have more hemodynamic instability during general anesthesia than do patients with normotension. in this study, the investigators evaluated the usefulness of carotid ultrasound and inferior vena cervical ultrasound for predicting hypotension after induction of anesthesia in patients with hypertension.

carotid and venous ultrasonography is performed in a comfortable state. corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. after inferior vena cava sonography, using the embedded software, the collapsibility index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. after confirming baseline blood pressure and pulse rate, propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / ml using the target control system (tci). following the administration of rocuronium 1.0-1.2 mg / kg, and 1 minute and 30 seconds after bis 60 or less, endotracheal intubation is performed using video laryngoscope. blood pressure and heart rate are measured at prior to induction, 1 minute after the induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. post-induction hypotension after anesthesia induction is considered as a decrease of 20% or more of the pre-anesthesia blood pressure or a mean arterial blood pressure of less than 60 mmhg. in the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.

Eligibility criteria:
inclusion criteria: * 1) 19-80 years old hypertensive patients with asa class i-iii * 2) scheduled surgery under general anesthesia exclusion criteria: * 1) emergency operation * 2) reoperation * 3) patients with history of heart failure (unstable angina, congestive heart failure, coronary artery disease) * 4) patients under 40 % of ejection faction * 5) patients with history of valvular heart failure * 6) patients with history of peripheral arterial occlusive disease * 7) patients with history of arrhythmia (specially av nodal block), ventricular conduction problem * 8) pregnancy patients * 9) patients who cannot read the consent form (examples: illiterate, foreigner) * 10) patients with history of uncontrolled psychiatric disease (ptsd, anxiety, depression) * 11) patients who withdraw the consent

Keywords: carotid sonography inferior vena cava sonography hypertension general anesthesia predictive power
effectiveness of stellate ganglion block for the treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the goal of this clinical trial is to test the efficacy of stellate ganglion block in obstructive sleep apnea. the main question it aims to answer are: • can stellate ganglion block improve obstructive sleep apnea? patients were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

obstructive sleep apnea is of increasingly high prevalence. the goal of this clinical trial is to test the efficacy of stellate ganglion block in obstructive sleep apnea. the main question it aims to answer are: • can stellate ganglion block improve obstructive sleep apnea? patients were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Eligibility criteria:
inclusion criteria: * patients aged over 18 years diagnosed with obstructive sleep apnea by polysomnography * patients with moderate to severe obstructive sleep apnea. * patients who have undergone continuous positive airway pressure (cpap) treatment for at least 3 months but have not achieved satisfactory therapeutic effects * patients who voluntarily agree to receive stellate ganglion block (sgb) treatment and sign the informed consent form exclusion criteria: * patients with a history of allergy or contraindications to local anesthetics or corticosteroids * patients with severe cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases * patients with a history of neck surgery or cervical spine disease * patients with psychiatric disorders or other medical conditions that may affect the safety or effectiveness of sgb treatment * pregnant or lactating women * patients who have participated in other clinical trials within the past 3 months
modified corneal ea with middle lkp for severe corneal burn

Conditions: Corneal Burn

Summary: the purpose of this pilot study is to explore whether modified corneal epithelial autograft (ea) combined with allogeneic middle lamellar keratoplasty (amlk) is more effective than limbal autograft (la) with amlk for ocular surface reconstruction in patients with severe corneal burn.


Eligibility criteria:
inclusion criteria: 1. unilateral severe corneal burn with more than half limbal stem cells deficiency (lscd). the history of the disease is at least 12 months at the time of screening visit. 2. presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea. 3. informed consent signed by a patient or legal guardian, or having the ability to comply with study assessments for the full duration of the study. exclusion criteria: 1. lscd of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement. 2. lscd by ocular surface disorders other than ocular burns. 3. eyelids malposition. 4. the center corneal thickness\<450µm, the depth of corneal opacity\<150µm or the full corneal lamellar opacity. 5. high myopia with a spherical equivalent of -15.0 d or less. 6. corneal or ocular surface infection within 30 days prior to study entry. 7. ocular surface malignancy. 8. uncontrolled diabetes with most recent hga1c greater than 8.5%. 9. renal failure with creatinine clearance ≤ 25ml/min per 1.73 m2. 10. alanine aminotransferase \> 40iu/l, or aspartate aminotransferase \> 40iu/l. 11. platelet levels \ 450,000 per microliter. 12. hemoglobin \< 12.0 g/dl (male) or \< 11.0 g/dl (female); 13. prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; an international normalized ratio greater than 3 in patients accepting anticoagulant therapy. 14. pregnancy (positive test) or lactation. 15. participation in another simultaneous medical investigation or clinical trial. 16. severe cicatricial eye disease; conjunctival scarring with fornix shortening. 17. ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases. 18. severe dry eye disease as determined by schirmer's test \< 2mm at least in one eye. 19. any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent. 20. signs of current infection, including fever and treatment with antibiotics.
study of erythropoietin to treat anemia complicating chronic obstructive pulmonary disease

Conditions: Anemia; Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine the impact of erythropoietin treatment of anemia on exercise capacity of patients with chronic obstructive pulmonary disease (copd).

the development of anemia in patients with chronic obstructive pulmonary disease (copd) is now taken as a predictor of increased morbidity and mortality. preliminary data from patients investigated in our department indicate a negative correlation between anemia severity and 6-minute walking distance. our working hypothesis is that hemoglobin level correction by erythropoietin therapy will improve the effort capacity of patients with copd and anemia. our objective is to conduct a pilot study of the efficacy of darbepoetin alfa. the study will include about 15 patients with copd recruited at three pulmonology centers based on two selection criteria: copd stage ii or iii or iv according to gold criteria and hemoglobin level less than 12 g/dl. effort capacity will be evaluated chiefly by performing a 6-minute walking test and by measuring vo2 at maximum exertion on a bicycle ergometer with increasing loads. darbepoetin alfa will be given for 2 months. if the hemoglobin increase is less than 1 g/dl after 1 month, the dosage will be increased by 25%. effort parameters will be measured at baseline and after 1 and 2 months of treatment. among secondary objectives, we will evaluate functional ergospirometric parameters and laboratory tests for inflammation. total study duration will not exceed 18 months.

Eligibility criteria:
inclusion criteria: * male and female aged 40-75 years * diagnosis of a moderate to very severe copd (stage ii, iii or iv according to gold criteria) * a ratio of post-bronchodilator fev1 to forced vital capacity (fvc) \< 70% * a fev1 \< 80% of the predicted value * hemoglobin level less than 12 g/dl * peak vo2 less than 80% of predict value and 6-min walk test distance less than 500 meters exclusion criteria: * hemorrhagic anemia * iron deficiency anemia (ferritin \< 30 ng/ml) * folate and vitamin b12 deficiency anemia * myelodysplastic syndrome * chronic disease associated with anemia: renal insufficiency, inflammatory disease, neoplastic disease, left ventricular insufficiency (ejection fraction \< 40%) * chronic disease likely to interfere with dyspnea or exercise testing (cardiac insufficiency, neurologic disease, claudication) * acute exacerbation of copd within the last 4 weeks * history of thromboembolic disease * contraindications for cardiopulmonary exercise testing * contraindications for darbepoetin alfa treatment: uncontrolled arterial hypertension or hypersensitivity reaction to darbepoetin alfa * pregnancy or breast-feeding (women of reproductive potential should use adequate birth control measures during the whole duration of study treatment)

Keywords: anemia chronic obstructive pulmonary disease erythropoietin 6-minute walk test
vitamin d and omega-3 trial: interrelationship of vitamin d and vitamin k on bone (vital)

Conditions: Bone Density; Bone Health; Fractures

Summary: vitamin d supplements are widely promoted for bone health. both vitamin d and vitamin k are important for deposition of calcium in bone, but little is known about the relationship of vitamin k status and bone health.

the goal of vital: interrelationship of vitamin d and vitamin k on bone is to test whether vitamin k status is associated with incident fractures in a case-cohort design or modifies the randomized effects of vitamin d supplementation vs. placebo on 2-year changes in bone density and structure outcomes.

Eligibility criteria:
inclusion: - participants in vital (nct 01169259) study who met the following criteria of the parent trial are eligible to participate in this ancillary study: * be men aged 50 years and older or women aged 55 years and older * have no history of cardiovascular disease or cancer (excluding non-melanoma skin cancer) * have none of the following: allergy to soy or fish, hypercalcemia, renal failure or dialysis, severe liver disease, hypo- or hyperparathyroidism, sarcoidosis or other granulomatous diseases, or any other serious illnesses * consume ≤ 1200 mg/d of calcium for the duration of the trial * consume ≤ 800 iu of vitamin d for duration of the trial * refrain from taking fish oil supplements for the duration of the trial exclusion: - for aims 2 and 3, those who are using bisphosphonates currently or within the past 2 years, or other bone-active medications currently or within the past year are not eligible for this study

Keywords: vitamin d vitamin k
polyamine-enriched diet in elderly individuals with subjective cognitive decline

Conditions: Subjective Cognitive Decline (SCD)

Summary: the overall objective of this study is to examine the effect of polyamine supplementation on cognitive performance and further characterization of individuals with subjective cognitive decline.

memory abilities are known to decline during aging, a process that is accelerated in pathological conditions like mild cognitive impairment (mci) and alzheimer's disease (ad), all of which are a growing public-health concern with devastating social and economical effects. polyamines supplementation and corresponding up-regulation of autophagy (i.e., cellular protein degradation pathways) may be a key target of intervention against age-related memory decline. the study will investigate whether a polyamine-enriched dietary supplementation (through capsule intake) could provide positive effects on cognitive function and biomarkers of elderly individuals (60-90 years old) with subjective cognitive decline (scd).

Eligibility criteria:
inclusion criteria: * cognitive healthy individuals with subjective memory decline and self-reported concerns * 60-90 years old * no manifest dementia (dsm-iv criteria) * no limitations in activities of daily living * capacity for consent exclusion criteria: * gluten, histamine or wheat seedling intolerance * severe neurological, internal or psychological diseases * advanced heart or respiratory diseases, severe arteriosclerosis, untreated thyroid disease or diabetes * malignant tumors, current or past history * brain tumors, stroke * disorders that impair attention * dementia * coagulation disorder, marcumar * drug abuse or alcohol dependency * current polyamine substitution

Keywords: subjective cognitive decline alzheimer's disease, dementia dietary supplement polyamine prevention treatment lifestyle memory autophagy
accuracy study for enhanced meter feature

Conditions: Diabetes Mellitus

Summary: this enhanced meter feature raises awareness among patients by providing additional information regarding their glycemic control between healthcare professional visits. this information may facilitate increased dialogue between patient and healthcare professionals and can remind patients of the importance of glycemic control. this study will evaluate a user's ability to obtain the enhanced meter feature.


Eligibility criteria:
inclusion criteria: * type i or type ii diabetes inclusive of the following populations: 1. mixed insulin therapies 2. basal insulin therapies 3. continuous subcutaneous insulin infusion therapies 4. multiple daily injection therapies 5. non-insulin diabetic treatments (oral and injectable) 6. life style (exercise and diet) diabetes management 7. new diagnosis of diabetes * non diabetics * able to speak and read english proficiently * subjects must be willing to: 1. once a month, perform a 7 point blood glucose profile over the course of one day 2. perform fasting blood glucose tests every day 3. complete baseline and follow-up questionnaires 4. consent to baseline hba1c assays exclusion criteria: * pregnant * hct \ 60 * work for bgm competitor company (including, but not limited to lifescan, roche, abbott) * homeless * incarcerated * mentally ill * employees or students of the research site, including the principal investigator, directly involved in the conduct of the protocol. * has any condition that the principal investigator believes may interfere in the subject's participation in the study.

Keywords: diabetes glucose glucometer
evaluation of consultation including genetic aspects of obesity

Conditions: Obesity

Summary: more than 1,000 obese people are screened for genetic mutations (mc4r). those with positive screenings as well as 320 randomly selected people without mc4r mutations are randomized to 2 consultation types: one including recommendations for eating and physical activity behavior, the other with an additional part on genetic determinants and actions in obesity. it is hypothesized that obese people with obesity-specific genetic mutations, and obese people with a family history of obesity, benefit more if the consultation includes additional elements on genetic determinants.

more than 1,000 obese people are screened for genetic mutations (mc4r). those with positive screenings as well as 320 randomly selected people without mc4r mutations are randomized to 2 consultation types: one including recommendations for eating and physical activity behavior, the other with an additional part on genetic determinants and actions in obesity. their results are compared to a control group (n\>100). it is hypothesized that obese people with obesity-specific genetic mutations, and obese people with a family history of obesity, benefit more if the consultation includes additional elements on genetic determinants. the following variables are used: bmi, scid interview for mental disorders, stunkard's body silhouttes for participants and their parents and siblings, restraint eating scale, panas, well-being scale, body acceptance, shame and guilt, coping with obesity, participant's satisfaction with consultation. assessment points: before consultation, after consultation, 6 months later.

Eligibility criteria:
inclusion criteria: * bmi \> 30 exclusion criteria: * brain damage

Keywords: obesity genetic consultation randomized controlled trial
investigating engagement patterns and participation trends among liposarcoma patients

Conditions: Liposarcoma

Summary: the study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific medical intervention. the primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. by joining this clinical study, individuals have the unique opportunity to contribute to the betterment of future liposarcoma patients and play an active role in advancing medical research.


Eligibility criteria:
inclusion criteria: * patient has self-identified as planning to enroll in a clinical research * patient has been diagnosed with liposarcoma * patient is a minimum of 18 years or older exclusion criteria: * patient does not understand, sign, and return consent form * inability to perform regular electronic reporting * patient is pregnant

Keywords: liposarcoma
acceptability and palatability study of paediatric amino acid feed

Conditions: Allergy

Summary: product acceptability and palatability data from a minimum of 15 participants are required to submit an application to the advisory committee on borderline substances (acbs) and the health service executive (hse) for ireland for product registration

the study product, alfamino junior (neutral or vanilla flavour) is a is a food for special medical purposes, as defined by eu regulation no 609/2013, acbs approved, prescribable on fp10 (gp10 in scotland). alfamino junior (neutral or vanilla flavour) is is for complete nutritional support of children ≥1 year with cows' milk allergy, multiple food allergies and other conditions where an amino acid formula is recommended. this is an open label nonrandomised acceptability, palatability and compliance study to evaluate the tolerance of the study formulas in 15 children. palatability is recorded over a 7day study period, acceptability is recorded days 1-7 and days 22-28 of the study period, with patient compliance recorded over the full 28 day study period

Eligibility criteria:
inclusion criteria: * children ≥1 year of age who require an amino acid-based formula (ideally already established on alfamino or another amino acid formula dependent on feasibility of reaching required numbers or currently on a plant-based milk and need extra nutrition from an amino acid formula) for the dietary management of presumed cma, or multiple food allergies and other conditions where an amino acid formula is recommended * all children ≥1 year of age where they are consuming either orally or via a tube 200mls or more of amino acid formula. * children with the ability to indicate palatability of the formula (nb there will be simple symbols to help young children and nonverbal children indicate whether the formula is palatable). if an infant is tube fed if they are able to have tastes orally. * willingly given, written, informed consent from patient or parent/guardian. exclusion criteria: * inability to comply with the study protocol, in the opinion of the investigator. * children less than 1 year of age * children with significant renal or hepatic impairment * change in current medication or use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator e.g. thickener, ppis etc (must be recorded in patient case record file). * participation in another intervention study within 2 weeks of this study. * caregiver unable to read and write in english (will need to complete 1 month of forms at home on behalf of participants).
ciprofloxacin for the prevention of meningococcal meningitis

Conditions: Meningitis, Meningococcal

Summary: this study evaluates the effect of antibiotic prophylaxis with ciprofloxacin, given to the contacts of meningitis cases, on the overall attack rate of meningitis during an epidemic. one third of enrolled villages will receive standard care; in one-third of villages, household contacts of meningitis cases will be offered a single dose of oral ciprofloxacin; and in one-third of villages, the entire village will be offered a single dose of oral ciprofloxacin after the notification of the first case in the village.

antibiotic prophylaxis is not currently recommended for contacts of cases during a meningitis epidemic in the african meningitis belt. reactive vaccination campaigns are the preferred strategy for prevention during an epidemic. a novel strain of meningococcus, neisseria meningitidis serogroup c (nmc), began circulating in nigeria in 2013 and caused a major epidemic with over 10 000 cases in nigeria and niger in 2015. there is currently a global shortage of vaccine against nmc, and a recent who expert panel called for the formal evaluation of antibiotic prophylaxis as another epidemic response strategy. when taken as a single dose, oral ciprofloxacin effectively eliminates nasopharyngeal carriage of meningococcus. this trial aims to investigate two different antibiotic prophylaxis strategies during an epidemic of meningococcal meningitis: ciprofloxacin prophylaxis to household members of cases and village-wide prophylaxis after the notification of a case in a village. these two strategies will be compared to villages receiving standard care.

Eligibility criteria:
inclusion criteria: * resident in a village included in the study area exclusion criteria: * patients currently exhibiting symptoms of meningitis (to be immediately referred for further care) * persons with a known allergy to fluoroquinolone antibiotics.

Keywords: neisseria meningitidis ciprofloxacin chemoprevention